Technical Report | Published:

Dissolving polymer microneedle patches for influenza vaccination

Nature Medicine volume 16, pages 915920 (2010) | Download Citation

Abstract

Influenza prophylaxis would benefit from a vaccination method enabling simplified logistics and improved immunogenicity without the dangers posed by hypodermic needles. Here we introduce dissolving microneedle patches for influenza vaccination using a simple patch-based system that targets delivery to skin's antigen-presenting cells. Microneedles were fabricated using a biocompatible polymer encapsulating inactivated influenza virus vaccine for insertion and dissolution in the skin within minutes. Microneedle vaccination generated robust antibody and cellular immune responses in mice that provided complete protection against lethal challenge. Compared to conventional intramuscular injection, microneedle vaccination resulted in more efficient lung virus clearance and enhanced cellular recall responses after challenge. These results suggest that dissolving microneedle patches can provide a new technology for simpler and safer vaccination with improved immunogenicity that could facilitate increased vaccination coverage.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Centers for Disease Control and Prevention. Influenza activity—United States and worldwide, 2007–08 season. MMWR Morb. Mortal. Wkly. Rep. 57, 692–697 (2008).

  2. 2.

    , , & Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369–393 (2009).

  3. 3.

    & Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 304, 247–268 (2006).

  4. 4.

    et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286–2294 (2004).

  5. 5.

    et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198, 650–658 (2008).

  6. 6.

    et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27, 454–459 (2009).

  7. 7.

    & Intradermal Delivery of Vaccines: A Review of the Literature and the Potential for Development for Use in Low- and Middle-Income Countries. (Program for Appropriate Technology in Health, Ferney Voltaire, France, 2009).

  8. 8.

    et al. Influence of needle gauge in Mantoux skin testing. Chest 106, 1463–1465 (1994).

  9. 9.

    & Transdermal drug delivery. Nat. Biotechnol. 26, 1261–1268 (2008).

  10. 10.

    , , & Effect of microneedle design on pain in human volunteers. Clin. J. Pain 24, 585–594 (2008).

  11. 11.

    et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8, 415–419 (2002).

  12. 12.

    et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24, 1653–1664 (2006).

  13. 13.

    et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 4, e4773 (2009).

  14. 14.

    et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. USA 106, 7968–7973 (2009).

  15. 15.

    et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201, 190–198 (2010).

  16. 16.

    et al. Sugar micro needles as transdermic drug delivery system. Biomed. Microdevices 7, 185–188 (2005).

  17. 17.

    , , , & Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J. Drug Target. 14, 255–261 (2006).

  18. 18.

    , & Dissolving microneedles for transdermal drug delivery. Biomaterials 29, 2113–2124 (2008).

  19. 19.

    , & Minimally invasive protein delivery with rapidly dissolving microneedles. Adv. Mater. 20, 933–938 (2008).

  20. 20.

    PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone). (Lewis Publishers, Chelsea, Michigan, 1990).

  21. 21.

    , & Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J. Control. Release 104, 51–66 (2005).

  22. 22.

    , & Methods for in vitro percutaneous absorption studies II. Animal models for human skin. Toxicol. Appl. Pharmacol. 62, 481–488 (1982).

  23. 23.

    & Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J. Immunol. 183, 4177–4181 (2009).

  24. 24.

    , , , & IL-21 up-regulates the expression of genes associated with innate immunity and TH1 response. J. Immunol. 169, 3600–3605 (2002).

  25. 25.

    et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630–1634 (2002).

  26. 26.

    et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005).

  27. 27.

    & The cost of unsafe injections. Bull. World Health Organ. 77, 808–811 (1999).

  28. 28.

    Immunization without needles. Nat. Rev. Immunol. 5, 905–916 (2005).

  29. 29.

    , & Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. N. Engl. J. Med. 247, 921–929 (1952).

  30. 30.

    & Toward a broadly protective influenza vaccine. J. Clin. Invest. 118, 3273–3275 (2008).

  31. 31.

    , & Probing the 'labyrinth' linking the innate and adaptive immune systems. Nat. Immunol. 8, 899–901 (2007).

  32. 32.

    & Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4, 211–222 (2004).

  33. 33.

    & Toll-like receptors in the skin. Semin. Immunopathol. 29, 15–26 (2007).

  34. 34.

    , , , & Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24, 6110–6119 (2006).

  35. 35.

    et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447–6457 (2007).

  36. 36.

    Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J. Virol. 14, 1307–1309 (1974).

  37. 37.

    & A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27, 493–497 (1938).

Download references

Acknowledgements

This study was carried out at the Emory Vaccine Center and the Georgia Tech Center for Drug Design, Development and Delivery and Institute for Bioengineering and Biosciences. The work was supported in part by US National Institutes of Health grants R01-EB006369 and U01-AI084579 and contract HHSN266200700006C. S.P.S. was a trainee supported by a fellowship from the US Department of Education Graduate Assistance in Areas of National Need program. M.d.P.M. was a trainee supported by contract HHSN266200700006C from the US National Institutes of Health–National Institute of Allergy and Infectious Diseases.

Author information

Author notes

    • Sean P Sullivan
    •  & Dimitrios G Koutsonanos

    These authors contributed equally to this work.

Affiliations

  1. Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, Georgia Institute of Technology, Atlanta, Georgia, USA.

    • Sean P Sullivan
    • , Niren Murthy
    •  & Mark R Prausnitz
  2. Department of Microbiology & Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.

    • Dimitrios G Koutsonanos
    • , Maria del Pilar Martin
    • , Richard W Compans
    •  & Ioanna Skountzou
  3. School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.

    • Jeong Woo Lee
    • , Vladimir Zarnitsyn
    • , Seong-O Choi
    •  & Mark R Prausnitz

Authors

  1. Search for Sean P Sullivan in:

  2. Search for Dimitrios G Koutsonanos in:

  3. Search for Maria del Pilar Martin in:

  4. Search for Jeong Woo Lee in:

  5. Search for Vladimir Zarnitsyn in:

  6. Search for Seong-O Choi in:

  7. Search for Niren Murthy in:

  8. Search for Richard W Compans in:

  9. Search for Ioanna Skountzou in:

  10. Search for Mark R Prausnitz in:

Contributions

S.P.S., D.G.K., M.d.P.M. and I.S. carried out most experimental studies; J.W.L. and V.Z. prepared microneedles and helped generate the Supplementary Data; S.-O.C. prepared the molds used to fabricate microneedles; S.P.S., D.G.K., I.S. and M.R.P. designed the study and its analysis; S.P.S., I.S. and M.R.P. wrote the manuscript; and N.M., R.W.C., I.S. and M.R.P. supervised the project.

Competing interests

M.R.P. serves as a consultant to and is an inventor on patents licensed to companies developing microneedle-based products. This possible conflict of interest is being managed by Georgia Tech and Emory University.

Corresponding authors

Correspondence to Ioanna Skountzou or Mark R Prausnitz.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Data, Supplementary Figures 1–3 and Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.2182

Further reading